Abstract | PURPOSE: EXPERIMENTAL DESIGN: To characterize heparanase regulation by estrogen and tamoxifen and its clinical relevance for breast tumorigenesis, we applied immunohistochemical analysis of tissue microarray combined with chromatin immunoprecipitation assay, reverse transcription-PCR, and Western blot analysis. RESULTS: CONCLUSIONS:
Heparanase induction by ligand-bound ER represents an important pathway in breast tumorigenesis and may be responsible, at least in part, for the failure of tamoxifen therapy in some patients. Our study provides new insights on breast cancer progression and endocrine therapy resistance, offering future strategies for delaying or reversing this process.
|
Authors | Irit Cohen, Bella Maly, Itamar Simon, Amichay Meirovitz, Eli Pikarsky, Eyal Zcharia, Tamar Peretz, Israel Vlodavsky, Michael Elkin |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 13
Issue 14
Pg. 4069-77
(Jul 15 2007)
ISSN: 1078-0432 [Print] United States |
PMID | 17634531
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Chromatin
- RNA, Neoplasm
- Receptors, Estrogen
- Tamoxifen
- heparanase
- Glucuronidase
|
Topics |
- Aged
- Aged, 80 and over
- Breast Neoplasms
(drug therapy, enzymology, pathology)
- Cell Division
(drug effects)
- Cell Line, Tumor
- Chromatin
(isolation & purification)
- Female
- Gene Expression Regulation, Neoplastic
(drug effects)
- Glucuronidase
(genetics)
- Humans
- Lymphatic Metastasis
- Middle Aged
- Polymerase Chain Reaction
- RNA, Neoplasm
(genetics)
- Receptors, Estrogen
(analysis)
- Tamoxifen
(therapeutic use)
|